Literature DB >> 23529742

A systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciatica.

Nefyn H Williams1, Ruth Lewis, Nafees Ud Din, Hosam E Matar, Deborah Fitzsimmons, Ceri J Phillips, Alex Sutton, Kim Burton, Maggie Hendry, Sadia Nafees, Clare Wilkinson.   

Abstract

PURPOSE: Systematic review comparing biological agents, targeting tumour necrosis factor α, for sciatica with placebo and alternative interventions.
METHODS: We searched 21 electronic databases and bibliographies of included studies. We included randomised controlled trials (RCTs), non-RCTs and controlled observational studies of adults who had sciatica treated by biological agents compared with placebo or alternative interventions.
RESULTS: We pooled the results of six studies (five RCTs and one non-RCT) in meta-analyses. Compared with placebo biological agents had: better global effects in the short-term odds ratio (OR) 2.0 (95 % CI 0.7-6.0), medium-term OR 2.7 (95 % CI 1.0-7.1) and long-term OR 2.3 [95 % CI 0.5 to 9.7); improved leg pain intensity in the short-term weighted mean difference (WMD) -13.6 (95 % CI -26.8 to -0.4), medium-term WMD -7.0 (95 % CI -15.4 to 1.5), but not long-term WMD 0.2 (95 % CI -20.3 to 20.8); improved Oswestry Disability Index (ODI) in the short-term WMD -5.2 (95 % CI -14.1 to 3.7), medium-term WMD -8.2 (95 % CI -14.4 to -2.0), and long-term WMD -5.0 (95 % CI -11.8 to 1.8). There was heterogeneity in the leg pain intensity and ODI results and improvements were no longer statistically significant when studies were restricted to RCTs. There was a reduction in the need for discectomy, which was not statistically significant, and no difference in the number of adverse effects.
CONCLUSIONS: There was insufficient evidence to recommend these agents when treating sciatica, but sufficient evidence to suggest that larger RCTs are needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529742      PMCID: PMC3777072          DOI: 10.1007/s00586-013-2739-z

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  30 in total

1.  Updated method guidelines for systematic reviews in the cochrane collaboration back review group.

Authors:  Maurits van Tulder; Andrea Furlan; Claire Bombardier; Lex Bouter
Journal:  Spine (Phila Pa 1976)       Date:  2003-06-15       Impact factor: 3.468

Review 2.  What can the history and physical examination tell us about low back pain?

Authors:  R A Deyo; J Rainville; D L Kent
Journal:  JAMA       Date:  1992-08-12       Impact factor: 56.272

3.  TNF-alpha blockade for herniated intervertebral disc-induced sciatica: a way forward at last?

Authors:  R G Cooper; A J Freemont
Journal:  Rheumatology (Oxford)       Date:  2003-09-16       Impact factor: 7.580

4.  Natural history and prognostic indicators of sciatica.

Authors:  Florence Tubach; Julien Beauté; Annette Leclerc
Journal:  J Clin Epidemiol       Date:  2004-02       Impact factor: 6.437

5.  Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain.

Authors:  Erin D Milligan; Evan M Sloane; Stephen J Langer; Travis S Hughes; Brian M Jekich; Matthew G Frank; John H Mahoney; Lindsay H Levkoff; Steven F Maier; Pedro E Cruz; Terence R Flotte; Kirk W Johnson; Melissa M Mahoney; Raymond A Chavez; Leslie A Leinwand; Linda R Watkins
Journal:  Pain       Date:  2006-09-01       Impact factor: 6.961

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam.

Authors:  H Weber; I Holme; E Amlie
Journal:  Spine (Phila Pa 1976)       Date:  1993-09-01       Impact factor: 3.468

8.  The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial.

Authors:  Timo Korhonen; Jaro Karppinen; Leena Paimela; Antti Malmivaara; Karl-August Lindgren; Chris Bowman; Anthony Hammond; Bruce Kirkham; Simo Järvinen; Jaakko Niinimäki; Nic Veeger; Marianne Haapea; Markus Torkki; Osmo Tervonen; Seppo Seitsalo; Heikki Hurri
Journal:  Spine (Phila Pa 1976)       Date:  2006-11-15       Impact factor: 3.468

9.  Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica.

Authors:  Jaro Karppinen; Timo Korhonen; Antti Malmivaara; Leena Paimela; Eero Kyllönen; Karl-August Lindgren; Pekka Rantanen; Osmo Tervonen; Jaakko Niinimäki; Seppo Seitsalo; Heikki Hurri
Journal:  Spine (Phila Pa 1976)       Date:  2003-04-15       Impact factor: 3.468

10.  Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial.

Authors:  Steven P Cohen; Ronald L White; Connie Kurihara; Thomas M Larkin; Audrey Chang; Scott R Griffith; Christopher Gilligan; Ralph Larkin; Benny Morlando; Paul F Pasquina; Tony L Yaksh; Conner Nguyen
Journal:  Ann Intern Med       Date:  2012-04-17       Impact factor: 51.598

View more
  9 in total

Review 1.  The Michel Benoist and Robert Mulholland Yearly European Spine Journal Review: a survey of the "medical" articles in the European Spine Journal, 2013.

Authors:  Michel Benoist
Journal:  Eur Spine J       Date:  2013-12-13       Impact factor: 3.134

2.  Comment on Williams NH, et al.: a systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciatica (Eur Spine J, 2013;22(9):1921-35).

Authors:  Jing Wang; Gui-tao Li; Hong-tao Sun
Journal:  Eur Spine J       Date:  2014-01-17       Impact factor: 3.134

Review 3.  Conservative treatments for lumbar radicular pain.

Authors:  Gregory Fleury; Michael J Nissen; Stéphane Genevay
Journal:  Curr Pain Headache Rep       Date:  2014-10

4.  Developments in intervertebral disc disease research: pathophysiology, mechanobiology, and therapeutics.

Authors:  Kathryn T Weber; Timothy D Jacobsen; Robert Maidhof; Justin Virojanapa; Chris Overby; Ona Bloom; Shaheda Quraishi; Mitchell Levine; Nadeen O Chahine
Journal:  Curr Rev Musculoskelet Med       Date:  2015-03

5.  Answer to the Letter to the Editor of Gui-Tao Li et al. concerning: "A systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciatica" by Williams NH, Lewis R, Din NU, Matar HE, Fitzsimmons D, Phillips CJ, Sutton A, Burton K, Hendry M, Nafees S, Wilkinson C (2013) Eur Spine J; 22:1921-1935.

Authors:  Nefyn H Williams; Ruth Lewis
Journal:  Eur Spine J       Date:  2014-01-17       Impact factor: 3.134

6.  Increased local expressions of CX3CL1 and CCL2 are related to clinical severity in lumbar disk herniation patients with sciatic pain.

Authors:  Zhen-Yu Peng; Rui Chen; Zuo-Zhong Fang; Bin Chen; Zhi-Hua Wang; Xi-Yang Wang
Journal:  J Pain Res       Date:  2017-01-17       Impact factor: 3.133

7.  Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC).

Authors:  Nefyn H Williams; Alison Jenkins; Nia Goulden; Zoe Hoare; Dyfrig A Hughes; Eifiona Wood; Nadine E Foster; David Walsh; Dawn Carnes; Valerie Sparkes; Elaine M Hay; John Isaacs; Kika Konstantinou; Dylan Morrissey; Jaro Karppinen; Stephane Genevay; Clare Wilkinson
Journal:  Trials       Date:  2018-07-31       Impact factor: 2.279

8.  Inflammatory biomarkers do not distinguish between patients with sciatica and referred leg pain within a primary care population: results from a nested study within the ATLAS cohort.

Authors:  Samantha L Hider; Kika Konstantinou; Elaine M Hay; John Glossop; Derek L Mattey
Journal:  BMC Musculoskelet Disord       Date:  2019-05-10       Impact factor: 2.362

Review 9.  Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.

Authors:  Ju-Fen Yeh; Aysen Akinci; Mohammed Al Shaker; Ming Hong Chang; Andrei Danilov; Rocio Guileen; Kirk Johnson; Yong-Chul Kim; Ahmed El-Shafei; Vladimir Skljarevski; Hector Duenas; Warat Tassanawipas
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.